Flash FinanceUS
Market open S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · HARVARD BIOSCIENCE INC (HBIO)

Harvard Bioscience Q3 revenue rises 8% to $22.2 million; net loss widens

Mixed Impact 3 of 5 earnings

Harvard Bioscience reported third quarter 2026 revenue of $22.2 million, up from $20.6 million a year earlier, but its net loss widened to $2.6 million from $1.2 million and adjusted EBITDA fell to $1.8 million from $2.0 million. The company reaffirmed its full-year 2026 revenue growth guidance of 3% to 5% and updated its full-year adjusted EBITDA target to growth of (1%) to 4%.

Key points

  • Q3 2026 revenue was $22.2 million, up 7.8% from $20.6 million in Q3 2025.
  • Q3 2026 net loss was $2.6 million, or $(0.58) per share, versus a net loss of $1.2 million in Q3 2025.
  • Q3 2026 adjusted EBITDA was $1.8 million, versus $2.0 million a year earlier.
  • Full-year 2026 guidance: revenue growth of 3% to 5%, adjusted gross margin of 57% to 59%, and adjusted EBITDA growth of (1%) to 4%.

The filing

CompanyHARVARD BIOSCIENCE INC (HBIO)
Form8-K, current report
Filed with the SECNov 10, 2026, 7:00 AM ET
Accession number0001171843-26-007308

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 10, 2026, 7:06 AM ET, from this filing only.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.